Lucid Diagnostics Receiving Medicare Payments For Its EsoGuard Esophageal DNA Test; Closed $15M Private Placement Of Its Newly Designated Series C Convertible Prefs To Existing Long-Term Shareholders On October 21

Benzinga

2026.10.22 20:28 (GMT+0)

Открыть на Benzinga